Skip to content
Empallo logo — Saving hearts.

Empallo

Saving hearts.

United States Boston, United States 10 employees Pre-Seed Total: $50.00K IT, Information Technology

General Information

Company Name Empallo
Location United States Boston, United States
Employees 10
Industries IT, Information Technology
Funding Stage Pre-Seed
Social

BounceWatch is an independent company data service, not affiliated with Empallo. To contact Empallo, visit empallo.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Empallo compare?

A PDF of Empallo and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Empallo soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Empallo

Empallo is a groundbreaking MIT spinoff dedicated to "Saving hearts." Leveraging AI technology, the company specializes in bringing value-based care to heart failure management. With operations spanning across multiple states, Empallo is poised for success as it enters its third year as an innovator in the management of HF.

Operating within the Information Technology sector, Empallo's headquarters are situated in the United States. The latest milestone for the company was a significant $50.00KPre Seed Round investment on 27 April 2023, with backing from The Roux Institute at Northeastern University.

Empallo's dynamic approach to heart failure management, coupled with the support of esteemed investors, positions the company as a compelling prospect for venture capital consideration. The potential for technological advancement and impact in the healthcare sector makes Empallo a promising investment opportunity.

Business keywords: AI-guided healthcare, Value-based care, Heart failure management, Machine learning algorithms, Personalized treatment strategies, Cardiovascular disease, Clinical trials, Healthcare innovation, MIT spinoff, Innovative healthcare solutions

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Pre Seed Round $50.00K 1
The Roux Institute at Northeastern University
27 Apr 2023

Empallo Alternatives & Competitors

View All Alternatives
Empallo vs
Verisma
Verisma United States

We do the hard work to make trust work.

Private Equity
626 employees
Cloud Infrastructure, IT
Empallo vs
BeSure Healthcare B.V.
BeSure Healthcare B.V. The Netherlands

Digital Health Platform for cardiovascular disease: AI and biofeedback-based remote monitoring, trea...

Grant
1 employees
AI, Analytics
Empallo vs

Manage Shrinkage With Sales Optimization Solutions

12 employees
IT, Information Technology

FAQ About Empallo

Saving hearts.
Empallo is headquartered in Boston, United States.
Empallo operates in IT and Information Technology. Its work centres on AI-guided healthcare, Value-based care, Heart failure management and Machine learning algorithms.
Empallo has approximately 10 employees.
Empallo has completed 1 funding round, raising a total of $50.00K. The latest funding stage is Pre-Seed.
Top alternatives and competitors to Empallo include Verisma, BeSure Healthcare B.V., Beyond Technology Marketing and Sales (Pty) Ltd, RubiconMD, Pet Universal. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Empallo and Verisma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Empallo, https://bouncewatch.com/company/empallo, updated 2 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout